Phaseline

Targets › SLC13A5

SLC13A5 (Na(+)/citrate cotransporter): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Other; next expected readout Dec 2030.

High-affinity sodium/citrate cotransporter that mediates the entry of citrate into cells, which is a critical participant of biochemical pathways. May function in various metabolic processes in which citrate has a critical role such as energy production (Krebs cycle), fatty acid synthesis, cholesterol synthesis, glycolysis, and gluconeogenesis. (UniProt, Q86YT5)

Open in Phaseline: the race on SLC13A5, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
TESS Research FoundationTSHA-105
AAV9-mediated gene therapy delivering SLC13A5
SLC13A5Phase 1SLC13A5 Citrate Transporter DisorderDec 2030

Conditions

SLC13A5 Citrate Transporter Disorder (1)

Modalities

small molecule (1)

Companies

TESS Research Foundation (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.